Oncology Laboratories News
-
Recognizing 10 years of philanthropic support for prostate cancer research
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs ...
-
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a new study in the Journal of Molecular Diagnostics on the Idylla™ GeneFusion Assay (RUO) for rapid detection of targetable fusions involving ALK, ROS1, RET, and NTRK1/2/3 and MET exon 14 skipping mutations. The ...
By Biocartis NV
-
Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update
Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended September 30, 2021, and provided a business update on its progress over the reporting period. “The unprecedented objective response rate we have ...
-
PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn vector, NG-350A, to Re-Engineer Advanced Cancers
Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist. IV dosing of NG-350A led to elevations in IL-12, IFNγ and IL-17 that were higher and sustained for longer than those reported for systemic CD40 agonists. ...
-
Immatics Announces First Quarter 2021 Financial Results and Business Update
Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarter ended March 31, 2021. “In the first quarter of 2021, we reported first anti-tumor activity at the initial dose levels of our ...
-
PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases
Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid tumors Data is currently being presented at the AACR Virtual Annual Meeting 2021 OXFORD, UK ...
-
PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration
OXFORD, UK – 7 April 2021: PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® ...
-
Thermo Fisher Scientific Expands GlobalAccess Sequencing Program
Thermo Fisher Scientific today announced the expansion of its GlobalAccess Sequencing Program to include laboratories working in oncology. Originally introduced to accelerate multi-institutional-led studies focused on SARS-CoV-2, the expanded program now provides support to labs facing significant constraints as a result of the global pandemic by offering faster access to comprehensive, ...
-
Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology
Clinical researchers who take a traditional sequential approach to analyze myeloid malignancies, a highly heterogeneous group of disorders, face a major hurdle: a laborious and time-consuming workflow. To simplify and accelerate the genomic profiling process, Thermo Fisher Scientific announced that the Ion Torrent Oncomine Myeloid Research Assay* will be available in 2020 to run on the newly ...
-
Agilent Technologies Introduces New Exome Optimized for Clinical Research Sequencing
Agilent Technologies Inc. (NYSE: A) today introduced the SureSelect Clinical Research Exome. The performance-optimized exome design was developed in collaboration with researchers from Emory University and the Children's Hospital of Philadelphia. SureSelect Human All Exon V5 was used as the core for the new design. Performance has been enhanced in disease-associated regions, providing 10 percent ...
-
Dako, an Agilent Technologies Company, and U.S.-based Merck & Co. to Collaborate on Companion Diagnostic Test for Analysis of Tumor PD-L1 Levels
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced a collaboration with Merck & Co., Inc. (known as MSD outside the United States and Canada, through an affiliate) to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer. The companion diagnostic test coming out of this ...
-
Agilent Technologies, Cell Line Genetics Collaborate on High-Throughput Cell-Line Characterization Services for Regenerative Medicine, Cancer Researchers
Agilent Technologies Inc. (NYSE: A) today announced a collaboration with Cell Line Genetics, Inc., a leading provider of cell-line characterization and quality assurance services. CLG will develop high-throughput, genomic characterization workflows to confirm and monitor the integrity of cell lines for translational and regenerative medicine research. The workflows will be based upon Agilent's ...
-
Agilent Technologies Expands Catalog of SureFISH Break-Apart Probes
Agilent Technologies Inc. (NYSE: A) today introduced SureFISH ALK, ROS1 and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization (FISH) products. Agilent now offers more than 450 FISH probes The majority of FISH probes available on the market use BAC technology. BAC probes target repeat regions, and probe choices are limited by ...
-
Agilent Technologies Joins Forces with Baylor College of Medicine to Provide Customized CGH Microarrays for Cancer, Prenatal and Postnatal Research
Agilent Technologies Inc. (NYSE: A) has announced it is collaborating with Baylor College of Medicine's Medical Genetics Laboratories to provide customized CGH (comparative genomics hybridization) microarrays to researchers worldwide. Six new microarray designs unite the power of Baylor's data-rich expertise in genetics research with Agilent's microarray manufacturing capabilities to enable ...
-
Agilent Technologies SureSelect Target Enrichment Now Available for Ion Proton Next-Generation Sequencing Systems
Agilent Technologies Inc. (NYSE: A) today introduced a new SureSelect target enrichment solution that allows Ion Proton users to realize the full power of their next-generation sequencers with the industry's leading human exome and custom DNA target enrichment solutions. SureSelect target enrichment is now available for all major sequencing platforms, enabling researchers to achieve the ...
-
Agilent Technologies introduces next-generation fluorescent in situ hybridization assays for molecular analysis
Agilent Technologies Inc. (NYSE: A) today introduced Agilent SureFISH probes, the next generation of fluorescent in situ hybridization (FISH) assays, delivering a comprehensive menu of the industry's highest resolution probes for a wide range of molecular analysis applications. Agilent SureFISH probes deliver dramatically better performance compared to existing FISH products. SureFISH probes ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you